文献速递慢性肾脏病

慢性肾脏病中的肠道屏障功能障碍:证据、机制与潜在临床意义

Intestinal barrier dysfunction in chronic kidney disease: evidence, mechanisms, and its potential clinical implications.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本范围综述系统评估了慢性肾脏病(CKD)中肠道通透性的实验与临床证据,检索截至2025年6月,纳入143项研究。结果显示晚期CKD和透析患者肠道通透性标志物升高,早期CKD结果不一,但研究异质性和偏倚风险限制结论。

要点

  • 晚期CKD和透析患者肠道通透性标志物升高,早期CKD结果不一致。
  • 动物模型显示屏障功能受损,体外模型脲毒暴露后通透性增加。
  • 研究异质性和高偏倚风险限制结论,需标准化方法和纵向临床研究。

核心结论

  • 当前证据支持CKD尤其晚期存在肠道屏障功能受损,但研究异质性和偏倚风险限制确定性结论。

研究设计与样本

  • 范围综述,检索Embase、PubMed、Web of Science、Cochrane Library和Scopus(2024年3月,2025年6月更新),纳入143项研究:6项体外、93项动物、36项人体、8项混合类型。

主要发现

  • 体外模型显示脲毒暴露后通透性增加,但紧密连接蛋白(TJP)表达变化不一致。
  • 动物模型显示屏障功能受损:异硫氰酸荧光素-葡聚糖评估通透性增加、跨上皮电阻降低、TJP表达减少。
  • 人体研究显示晚期CKD和透析患者通透性生物标志物升高,早期疾病结果可变。
  • 有限人体数据提示occludin表达降低。
  • 观察到肠道通透性与全身炎症、胃肠道症状、肌少症和肾脏结局的关联,但属初步。

临床怎么用

  • 临床可关注晚期CKD和透析患者肠道屏障功能,但目前证据尚不足以指导靶向干预。

局限性

  • 体外和动物数据偏倚风险高且缺乏功效计算。
  • 研究异质性和频繁偏倚风险限制确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The gut-kidney axis plays a critical role in chronic kidney disease (CKD), with evidence suggesting that intestinal barrier dysfunction contributes to systemic inflammation and toxin accumulation. However, findings remain inconsistent due to heterogeneous study designs and outcome measures. This scoping review systematically assessed experimental and clinical evidence on gut permeability in CKD and identified gaps in current knowledge. We searched Embase, PubMed, Web of Science, Cochrane Library, and Scopus (March 2024; updated June 2025) using a protocol registered on the Open Science Framework. Eligible studies investigated intestinal barrier function in CKD with a control group. Two reviewers screened records, assessed risk of bias with the Office of Health Assessment and Translation tool, and extracted data on permeability markers, tight junction proteins (TJPs), and related outcomes. Of 10 661 records screened, 143 studies were included: 6 in vitro, 93 animal, 36 human, and 8 papers with a combination of study types. In vitro models showed increased permeability after exposure to uremic toxins, although effects on TJP expression were inconsistent. Animal models demonstrated impaired barrier function as assessed by Fluorescein isothiocyanate-dextran, reduced transepithelial electrical resistance, and decreased expression of the TJPs. Human studies reported elevated biomarkers of permeability in advanced CKD and dialysis, while early-stage disease showed variable results. Limited human data indicated reduced occludin expression. Associations between gut permeability, systemic inflammation, gastrointestinal symptoms, sarcopenia, and kidney outcomes were observed, but remain preliminary. Interpretation of the results should consider the high level of bias and the lack of power calculations in both the in vitro and animal data. Current evidence supports impaired intestinal barrier function in CKD, particularly in advanced stages. However, study heterogeneity and frequent risk of bias limit firm conclusions. Standardized methods and longitudinal clinical studies are needed to clarify the role of gut permeability in CKD progression and to evaluate whether barrier-targeted interventions may improve outcomes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zadora W, Jacobs E, Lauriola M, et al. Intestinal barrier dysfunction in chronic kidney disease: evidence, mechanisms, and its potential clinical implications. Nephrol Dial Transplant. 2026. PMID: 42009296. doi:10.1093/ndt/gfag082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。